Brain Cancer
Findings from Duke University, Preston Robert Tisch Brain Tumor Center provide new insights into brain cancer
Published in Proteomics Weekly, August 4th, 2008
"We determined the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of imatinib mesylate, an inhibitor of the receptor tyrosine kinases platelet-derived growth factor receptor (PDGFR), the proto-oncogene product c-kit, and the fusion protein Bcr-Abl, when administered for 8 days in combination with temozolomide (TMZ) to malignant glioma (MG) patients. MG patients who had not failed prior TMZ were eligible to receive TMZ at a dose of 150-200 mg/m(2) per day on days 4-8 plus imatinib mesylate administered orally on days 1-8 of each 4-week cycle," scientists in the United States report.
"Patients were stratified based on concurrent administration of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Proteomics Weekly
Source: Proteomics Weekly (2008-08-04)
More Articles from Proteomics Weekly
- Massachusetts General Hospital
Viral recombination another way HIV fools the immune system - Alfacell Corporation
Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacell's ONCONASE and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines - Applied Biosystems Inc.
Scientists Report Most Comprehensive View of Mammalian Transcriptome - Cancer
Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacell's ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines - DNA Vaccines
New findings in DNA vaccines described from Fourth Military Medical University - Enzyme Research
Recent studies by J.Z. Stoller and co-authors add new data to enzyme research findings - More from this issue of Proteomics Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
